Unión Europea - español - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - neoplasmas prostáticos - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Unión Europea - español - EMA (European Medicines Agency)

eli lilly nederland b.v. - olaratumab - sarcoma - agentes antineoplásicos - lartruvo está indicado en combinación con doxorrubicina para el tratamiento de pacientes adultos con sarcoma de tejidos blandos que no son susceptibles de tratamiento curativo con cirugía o radioterapia y que no han sido previamente tratadas con doxorrubicina (véase sección 5.

Unión Europea - español - EMA (European Medicines Agency)

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - agentes antineoplásicos - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

Unión Europea - español - EMA (European Medicines Agency)

eli lilly nederland b.v. - abemaciclib - neoplasias de la mama - agentes antineoplásicos - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.

Unión Europea - español - EMA (European Medicines Agency)

eli lilly nederland b.v. - lasmiditan succinate - trastornos de la migraña - analgésicos - rayvow is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.

Unión Europea - español - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artritis, reumatoide - inmunosupresores - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant puede usarse como monoterapia o en combinación con metotrexato. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Unión Europea - español - EMA (European Medicines Agency)

eli lilly nederland b.v. - pirtobrutinib - linfoma, célula del manto - inhibidores de la proteína quinasa - treatment of mantle cell lymphoma (mcl).

Unión Europea - español - EMA (European Medicines Agency)

chemical works of gedeon richter plc. (gedeon richter plc.) - ganirelix acetate - reproductive techniques, assisted; ovulation induction; infertility, female - hormonas hipofisarias e hipotalámicas y análogos - prevention of premature luteinising hormone (lh) surges in women undergoing controlled ovarian hyperstimulation (coh) for assisted reproduction techniques (art).

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

eli lilly and company ltd - fentanilo - soluciÓn transdÉrmica - excipientes: isopropilico, alcohol - fentanilo - perros

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

eli lilly and company ltd - pegbovigrastim - soluciÓn inyectable - excipientes: citrico acido, monohidrato, l-arginina, agua para preparaciones inyectables, arginina, hidrocloruro de - pegbovigrastim - novillas, vacas